New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...

Fulvestrant is an analog of 17B-estradiol that binds the estrogen receptor (ER) with a similar affinity to the parent molecule. 3 However, because of the alkinylsulphinyl side chain in the 7-alpha ...

All patients received prior palbociclib: 14 patients with an AI, 6 patients with fulvestrant, and 1 patient received palbociclib with an AI and then with fulvestrant. Of the 21 patients, 17 were ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...